Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | KDM4B | O94953 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 6/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6438274 | 1.00 | KDM4A (0.49) | KDM4AKDM4BMAPTALDH1A1VCAM1 | |
| SCHEMBL1465907 | 0.92 | ALDH1A1 (0.49) | KDM4AKDM4BMAPTALDH1A1VCAM1 | |
| SCHEMBL1465908 | 0.92 | ALDH1A1 (0.49) | KDM4AKDM4BMAPTALDH1A1VCAM1 | |
| SCHEMBL6609820 | 0.89 | ALDH1A1 (0.49) | KDM4AKDM4BMAPTALDH1A1VCAM1 | |
| SCHEMBL6609823 | 0.89 | ALDH1A1 (0.49) | KDM4AKDM4BMAPTALDH1A1VCAM1 | |
| SCHEMBL13365085 | 0.88 | ALDH1A1 (0.43) | KDM4AKDM4BMAPTALDH1A1VCAM1 | |
| SCHEMBL11614092 | 0.85 | ALDH1A1 (0.50) | KDM4AKDM4BMAPTALDH1A1PTGS2 | |
| SCHEMBL7445274 | 0.82 | MAPT (0.44) | KDM4AKDM4BMAPTALDH1A1VCAM1 | |
| SCHEMBL7445278 | 0.82 | MAPT (0.44) | KDM4AKDM4BMAPTALDH1A1VCAM1 | |
| SCHEMBL6616919 | 0.81 | PTGS2 (0.40) | KDM4AKDM4BMAPTALDH1A1VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10279538-A | — | — | None | — | — | JP | disclosed |
| EP-1042316-B1 | INDOLE DERIVATIVES USEFUL A.O. FOR THE TREATMENT OF OSTEOPOROSIS | NIKEM RESEARCH SRL (IT) | 2005-02-09 | — | — | EP | disclosed |
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | FARINA CARLO (IT) | 2004-11-25 | — | — | US | disclosed |
| EP-1212317-B1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | NIKEM RESEARCH SRL (IT) | 2004-09-15 | — | — | EP | disclosed |
| US-6787550-B1 | 4-(5,6-DICHLORO-1H-INDOL-2-YL)-3-ETHOXY-N-(2,2,6,6 -TETRAMETHYLTETRAMETHYLPIPERIDIN-4-YL)-BENZAMIDE | NIKEM RESEARCH S.R.L. (IT) | 2004-09-07 | — | — | US | disclosed |
| US-6506758-B2 | 4-(5,6-dichloro-1H-indol-2-yl)-N-(1,2,2,6,6-pentamethyl -piperidin-4-yl)benzamide, for example; selective for mammalian osteoclasts, acting to selectively inhibit their bone resorbing activity | SMITHKLINE BEECHAM LABORATOIRES PHARMCEUTIQUES (FR) | 2003-01-14 | — | — | US | disclosed |
| US-20020099080-A1 | Indole derivatives useful A.O. for the treatment of osteoporosis | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES | 2002-07-25 | — | — | US | disclosed |
| EP-1042316-A1 | INDOLE DERIVATIVES USEFUL A.O. FOR THE TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033822-A1 | INDOLE DERIVATIVES USEFUL A.O. FOR THE TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1999-07-08 | — | — | WO | disclosed |
| JP-H10279538-A | 2-NITRO-POLYHALOGEN-SUBSTITUTED-BETA-DIALKYLAMINOSTYRENE DERIVATIVE | IHARA CHEM IND CO LTD | 1998-10-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099080-A1 | Indole derivatives useful A.O. for the treatment of osteoporosis | SOST, NR3C2, EBP | KDM4A 2035/4885KDM4B 2077/4885MAPT 2331/4885 |
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | MALT1, SOST, NFATC1 | KDM4A 2202/4885KDM4B 2650/4885MAPT 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.